Literature DB >> 28869077

Current approaches to the treatment of Parkinson's Disease.

J Michael Ellis1, Matthew J Fell2.   

Abstract

Parkinson's Disease (PD) is the second most common neurodegenerative disorder. Clinical approaches to manage PD include symptomatic therapies, serving to compensate for the effects of dopaminergic neuronal deficits, as well as more recently a move toward disease modification, with the goal of slowing or stopping disease progression. This perspective surveys the approved therapies for PD treatment as well as provides a view of the ongoing clinical approaches aimed at improving outcomes for PD patients.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disease modification; Dopamine; Neurodegeneration; Parkinson’s Disease; Symptomatic; α-Synuclein

Mesh:

Substances:

Year:  2017        PMID: 28869077     DOI: 10.1016/j.bmcl.2017.07.075

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  22 in total

1.  Cinnamic Acid Protects the Nigrostriatum in a Mouse Model of Parkinson's Disease via Peroxisome Proliferator-Activated Receptorα.

Authors:  Tim Prorok; Malabendu Jana; Dhruv Patel; Kalipada Pahan
Journal:  Neurochem Res       Date:  2019-01-05       Impact factor: 3.996

2.  Pharmacophore modeling and 3D-QSAR study for the design of novel α-synuclein aggregation inhibitors.

Authors:  Jixia Yang; Jiajing Hu; Gongzheng Zhang; Li Qin; Hongliang Wen; Yun Tang
Journal:  J Mol Model       Date:  2021-08-25       Impact factor: 1.810

Review 3.  Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Authors:  Dharmendra Kumar Khatri; Amey Kadbhane; Monica Patel; Shweta Nene; Srividya Atmakuri; Saurabh Srivastava; Shashi Bala Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-04-08

4.  Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates Behavioral Changes in an MPTP Induced Parkinson's Disease Mouse Model.

Authors:  Rongni He; Wei Huang; Yaowei Huang; Miaojing Xu; Pingping Song; Yinwei Huang; Huifang Xie; Yafang Hu
Journal:  Front Aging Neurosci       Date:  2018-06-01       Impact factor: 5.750

5.  Synergistic Neuroprotective Effect of Endogenously-Produced Hydroxytyrosol and Synaptic Vesicle Proteins on Pheochromocytoma Cell Line Against Salsolinol.

Authors:  Robina Manzoor; Aamir Rasool; Maqbool Ahmed; Ullah Kaleem; Lucienne Nneoma Duru; Hong Ma; Yulin Deng
Journal:  Molecules       Date:  2020-04-08       Impact factor: 4.411

6.  Design, Synthesis, and Neuroprotective Effects of a Series of Pyrazolines against 6-Hydroxydopamine-Induced Oxidative Stress.

Authors:  Ahmet Özdemir; Belgin Sever; Mehlika Dilek Altıntop; Elif Kaya Tilki; Miriş Dikmen
Journal:  Molecules       Date:  2018-08-27       Impact factor: 4.411

7.  Exploring the Therapeutic Potentials of Highly Selective Oxygenated Chalcone Based MAO-B Inhibitors in a Haloperidol-Induced Murine Model of Parkinson's Disease.

Authors:  Della Grace Thomas Parambi; Uzma Saleem; Muhammad Ajmal Shah; Fareeha Anwar; Bashir Ahmad; Amna Manzar; Aqsa Itzaz; Seetha Harilal; Md Sahab Uddin; Hoon Kim; Bijo Mathew
Journal:  Neurochem Res       Date:  2020-09-16       Impact factor: 3.996

Review 8.  Understanding Miro GTPases: Implications in the Treatment of Neurodegenerative Disorders.

Authors:  Laura Kay; Ilse S Pienaar; Ruwini Cooray; Gary Black; Meera Soundararajan
Journal:  Mol Neurobiol       Date:  2018-02-06       Impact factor: 5.590

9.  Oxyphylla A Promotes Degradation of α-Synuclein for Neuroprotection via Activation of Immunoproteasome.

Authors:  Hefeng Zhou; Shengnan Li; Chuwen Li; Xuanjun Yang; Haitao Li; Hanbing Zhong; Jia-Hong Lu; Simon Ming-Yuen Lee
Journal:  Aging Dis       Date:  2020-05-09       Impact factor: 6.745

10.  Clinical Effects of Piribedil in Adjuvant Treatment of Parkinson's Disease: A Meta-Analysis.

Authors:  Lu Peihua; Wang Jianqin
Journal:  Open Med (Wars)       Date:  2018-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.